Retatrutide vs Semaglutide: Triple Agonist Meets Single Agonist
By Peptura Research Team/7 May 2026/7 min read
Starting Point
Retatrutide and Semaglutide are two of the most actively researched incretin-based peptides in metabolic science. Both are studied for their effects on glucose homeostasis and body composition, yet pharmacologically they are quite different animals. Semaglutide is a single-receptor GLP-1 agonist from Novo Nordisk, first approved for type 2 diabetes. Retatrutide, from Eli Lilly and currently in Phase 3 clinical trials, is a triple agonist that engages GIP, GLP-1, and glucagon receptors at once.
For labs sourcing either compound in the UK, Retatrutide 10mg is supplied at 99.6% HPLC-verified purity with full third-party batch documentation.
Mechanism of Action
Semaglutide works through a single receptor, the GLP-1 receptor, concentrated in pancreatic β-cells, the central nervous system, and the gastrointestinal tract. Activating it modulates glucose-dependent insulin secretion, slows gastric emptying, and shapes appetite through central pathways.
Retatrutide keeps that GLP-1 activity and stacks two more on top: GIP receptor agonism, which influences both insulin and glucagon secretion in glucose-dependent settings, and glucagon receptor agonism, which reaches hepatic glucose output and energy expenditure. Firing all three at once produces a profile no single or dual agonist can reproduce, which is what makes Retatrutide such a distinctive tool for studying multi-receptor crosstalk.
What the Phase 2 Data Show
Semaglutide carries an extensive clinical record, with multiple Phase 3 trials and regulatory approvals across diabetes and weight management. Published data report meaningful body-weight reductions in trial populations over 68-week treatment periods.
Retatrutide's Phase 2 results, published in the New England Journal of Medicine in 2023, showed body-weight reductions over 48 weeks well beyond what single GLP-1 agonists typically report at comparable timepoints. The triple-receptor mechanism appears to amplify energy expenditure through hepatic and thermogenic pathways that Semaglutide does not engage.
Choosing Between Them in Research
Semaglutide suits work that isolates GLP-1 receptor pharmacology, particularly models of pancreatic β-cell function, gastric motility, or central appetite regulation. Retatrutide is the molecule to reach for when the question turns on multi-receptor synergy, hepatic glucose handling, or energy-expenditure pathways that need glucagon receptor engagement.
Both appear across models of insulin sensitivity, lipid metabolism, and metabolic disease, but Retatrutide's broader reach makes it especially fitting for research into receptor crosstalk.
Laboratory Handling
Both peptides ship as lyophilised powders and need reconstituting with bacteriostatic water before use. Store lyophilised vials at -20°C and reconstituted solution at 2-8°C, using within four weeks. Run the bacteriostatic water down the inner wall of the vial and swirl gently, never shake. Our reconstitution guide covers the full protocol.
Sourcing in the UK
Peptura supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg in the UK with third-party HPLC documentation, batch PEP-742, same-day dispatch on orders before 2pm GMT, and free Royal Mail Tracked shipping over £45. Strictly for in-vitro laboratory research only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.